相关实验视频
Updated: Jun 14, 2026
06:33
Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
7.8K
血蛋白质组剖析揭示了V30M中Transthyretin多神经病变的炎症标志物和Tafamidis效应
Karina Nugroho1, Chung-Yon Lin1, Cecilia Monteiro1
1Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
International journal of molecular sciences
|June 26, 2025
概括
这项研究揭示了 transthyretin amyloidosis (ATTRv-PN) 患者和携带者的血蛋白质组变化. 塔法米迪斯治疗逆转了一些与疾病相关的变化,为疾病进展和治疗反应提供了洞察力.
科学领域:
- 生物化学 生物化学
- 蛋白质组学是指蛋白质组学.
- 遗传学 遗传学是一种遗传学.
背景情况:
- 晶氨酸 (TTR) 变体 (V30M) 多神经病变 (ATTRv-PN) 是一种渐进的氨基粉症.
- 由于TTR聚合,导致衰弱性神经病变和心肌病变.
研究的目的:
- 为了研究无症状V30M TTR载体和ATTRv-PN患者的血蛋白质组变化.
- 为了确定疾病进展和对tafamidis的治疗反应的生物标志物.
- 了解氧化应激在ATTRv-PN病变发生中的作用.
主要方法:
- 使用有机溶剂诱导的可溶性测定转移的等离子体蛋白质组分析.
- 对V30M TTR载体,ATTRv-PN患者 (塔法米迪斯前后) 和健康对照进行比较.
- 对蛋白质丰富度和降水敏感度的分析.
主要成果:
- 鉴定了TTR,阿波利波蛋白,血红和先天免疫蛋白的变化.
- 在ATTRv-PN患者中增加了TTR和APOE的氧化变异.
- 塔法米迪斯治疗缓解了与病理相关的蛋白质变化.
结论:
- 为V30M ATTRv-PN患者和携带者提供了全面的血蛋白质组概况.
- 获得了关于ATTRv-PN病理生理学和氧化应激的影响的见解.
- 确定了疾病进展和tafamidis反应的潜在生物标志物,突出了针对个性化amyloidosis治疗的蛋白质组.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...